<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>: iStockAnalyst.com  Symbols Feed</title>
    <link>http://www.istockanalyst.com</link>
    <description>Custom RSS Feed</description>
    <generator>http://www.iStockAnalyst.com</generator>
    <pubDate>Sun, 06 Dec 2009 07:32:42 GMT</pubDate>
    <language>en</language>
    <ttl>30</ttl>
    <item>
      <title>The Deep, Inner Meaning Of Bank of America's (BAC) TARP Repayment</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3688027</guid>
      <description><![CDATA[As expected, Bank of America (BAC) will repurchase its $45 billion TARP preferreds, funded in part by an additional $18.8 billion in &quot;common stock equivalents&quot;, $4.0 billion in asset sales, and $1.7 billion in restricted stock issued to employees in lieu of cash bonuses.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3688027>[More...]</a>]]></description>
      <pubDate>Fri, 04 Dec 2009 14:19:07 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BAC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WFC</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3688027</link>
    </item>
    <item>
      <title>Forget Yesterday, It's All About Jobs</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3687896</guid>
      <description><![CDATA[Good morning. Stocks tanked in the last half-hour on Thursday and while the major news outlets attributed the decline to either profit taking or some trepidation in front of this morning's big Jobs report, we'd like to offer a little more substantial reason for the 85 point dive on an otherwise subdued day of trading.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3687896>[More...]</a>]]></description>
      <pubDate>Fri, 04 Dec 2009 13:21:30 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AKAM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AKS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CVLT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">FSLR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GPRO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">JNPR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MCK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MRVL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NFLX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NVLS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TCO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TXN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">V</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VRSN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3687896</link>
    </item>
    <item>
      <title>Fed Balance Sheet Declines By $15 Billion After Improbable Reduction In MBS, Excess Reserves, Monetary Base Hit Record</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3686922</guid>
      <description><![CDATA[The Federal Reserve's balance sheet declined by $15 billion to $2,183 billion from the prior week, after the Fed presumably offloaded $2.7 billion in MBS: this is the first time since QE started that MBS holdings have declined. If anyone can tell us just who the idiots are who bought MBS from the Fed (and at what price), and who the even greater idiots are who are supposed to believe this, please send us an email.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3686922>[More...]</a>]]></description>
      <pubDate>Fri, 04 Dec 2009 04:14:41 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">FNM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">FRE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3686922</link>
    </item>
    <item>
      <title>A Busy Month For Immunogen (Part II)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3685816</guid>
      <description><![CDATA[At ASH 2009, Immunogen (IMGN) and its partners will present clinical data on three compounds: Sanofi-Aventis’ (SNY) SAR3419, Immunogen’s IMGN901 and Biotest’s BT-062.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3685816>[More...]</a>]]></description>
      <pubDate>Thu, 03 Dec 2009 21:03:11 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLDA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">IMGN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MITI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SNY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3685816</link>
    </item>
    <item>
      <title>China Will Continue To Drive The Global Economic Recovery In 2010</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3683989</guid>
      <description><![CDATA[China isn’t just leading the global economic recovery – it’s lapping the field.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3683989>[More...]</a>]]></description>
      <pubDate>Thu, 03 Dec 2009 14:38:07 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GROW</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">LFC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VALE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3683989</link>
    </item>
    <item>
      <title>Interesting Stat: How Much Private Sector GDP Is From Construction And Real Estate?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3683785</guid>
      <description><![CDATA[Back in June, we discussed commercial real estate at length following attendance at a large real estate conference in NYC. Our tone was cautious and one question we wondered about was the percentage of GDP that real estate represents. We actually came across the answer back in August and meant to share then, but didn't get to it. Since the question/topic remains highly relevant to considering the potential negative economic drag from depressed real estate activity, we're sharing now -- the following table is from an 8/28/09 NYTs article, &quot;Construction That Fueled Growth in the Sun Belt Slows&quot;:<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3683785>[More...]</a>]]></description>
      <pubDate>Thu, 03 Dec 2009 13:15:56 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BNI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3683785</link>
    </item>
    <item>
      <title>Credit Market Overview:  Dec 3, 2009</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3683773</guid>
      <description><![CDATA[The credit crunch crisis of confidence which we appear to be crawling out of even though the debt and equity markets catapulted themselves higher earlier this year could be similarly argued to be a crisis that started in the credit markets which crunched confidence around the world as it could a collapse in confidence in the value of the securities investors held which corrupted the credit markets causing them to cease funding.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3683773>[More...]</a>]]></description>
      <pubDate>Thu, 03 Dec 2009 12:59:02 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">XOM</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3683773</link>
    </item>
    <item>
      <title>Thermal technology puts con on hot seat</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3674737</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Dec. 1--Like the Beatles, Suffolk District Attorney Daniel Conley and Boston police have discovered that happiness is a warm gun. &lt;/li&gt;&lt;li&gt;That's because a Dorchester man has become the first defendant convicted of pistol possession by a Massachusetts jury based on thermal imaging evidence. &lt;/li&gt;&lt;li&gt;Giving new meaning to the catchphrase &quot;packing heat,&quot; investigators used the technology to successfully link the warmth from 25-year-old Jose Rodrigues' hand to a loaded 9mm Smith &amp; Wesson handgun they found in a snowbank in Dorchester on Jan. 12 as they were chasing him.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3674737>[More...]</a>]]></description>
      <pubDate>Tue, 01 Dec 2009 05:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SWHC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3674737</link>
    </item>
    <item>
      <title>Fewer new jobs in county in the third quarter</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3664871</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Nov. 25--Prince William gained 407 new jobs in the third quarter that runs between July and September, according to figures compiled and released by the Economic Development Department on Tuesday. &lt;/li&gt;&lt;li&gt;By comparison, the county saw 478 new jobs for the first quarter, January through March, and 599 in the second quarter, April through June. &lt;/li&gt;&lt;li&gt;The 119-year-old union brings an investment of $5.7 million and provides jobs for 38, according to the Economic Development Department.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3664871>[More...]</a>]]></description>
      <pubDate>Wed, 25 Nov 2009 11:50:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3664871</link>
    </item>
    <item>
      <title>Rare plant thought to be discovered near Doyle Drive project</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3635823</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Nov. 14--A plant not seen in 67 years and presumed extinct in the wild appears to have miraculously survived near Doyle Drive in the Presidio in San Francisco. &lt;/li&gt;&lt;li&gt;A lone Franciscan Manzanita was revealed last month after crews cleared trees as part of the Doyle Drive reconstruction project. &lt;/li&gt;&lt;li&gt;DNA testing is also under way, with results due back in early December.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3635823>[More...]</a>]]></description>
      <pubDate>Sat, 14 Nov 2009 03:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3635823</link>
    </item>
    <item>
      <title>Qiagen acquires SABiosciences</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3626399</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Nov. 11--Frederick -based SABiosciences Corp. has been sold to Qiagen, a leading provider of sample technologies for research. &lt;/li&gt;&lt;li&gt;The purchase agreement is for $90 million and expected to close in late December. &lt;/li&gt;&lt;li&gt;Given that the acquisition is pending approval of regulatory authorities, it is premature to comment on the products and personnel impact,&quot; said Jeffrey Hung, senior director of marketing for SABiosciences.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3626399>[More...]</a>]]></description>
      <pubDate>Wed, 11 Nov 2009 16:50:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">QGEN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">RNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SAB</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3626399</link>
    </item>
    <item>
      <title>Jury convicts N.J. man of southside Lebanon bank robbery</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3616993</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Nov. 7--A federal jury has convicted a New Jersey man of robbing a southside Lebanon bank more than five years ago, the U.S. Attorney's office reported this week. &lt;/li&gt;&lt;li&gt;The verdict was returned after a three-day trial before U.S. District Court Chief Judge Yvette Kane. &lt;/li&gt;&lt;li&gt;The charges stem from the April 15, 2004, armed robbery of M&amp;T Bank, 837 Quentin Road.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3616993>[More...]</a>]]></description>
      <pubDate>Sat, 07 Nov 2009 07:45:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MTB</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3616993</link>
    </item>
    <item>
      <title>Carnegie Mellon exhibit blurs line between artist, tools</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3613065</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Nov. 5--Art that whispers, learns and evolves is on display at Carnegie Mellon University's recently opened Gates Center for Computer Science. &lt;/li&gt;&lt;li&gt;The class was jointly taught last spring by Carlos Guestrin, an associate professor of computer science and machine learning at Carnegie Mellon's School of Computer Science, and Osman Khan, a visiting associate professor of art in the College of Fine Arts. &lt;/li&gt;&lt;li&gt;The seventh work, &quot;Generation 243,&quot; was created by Scott Draves, a software artist who received his doctorate in 1997 from the computer science department.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3613065>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 03:52:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3613065</link>
    </item>
    <item>
      <title>The News and Advance, Lynchburg, Va., Darrell Laurant Column: A Problem That Needs to Be Addressed</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3577875</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Oct. 25--(Second in a series) &lt;/li&gt;&lt;li&gt;To those, let me offer a third -- the certainty that politicians will use taxes as a blunt instrument to wield against their opponents. &lt;/li&gt;&lt;li&gt;This fall, for example, both candidates for Virginia governor are accusing the other of plotting to raise taxes.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3577875>[More...]</a>]]></description>
      <pubDate>Sun, 25 Oct 2009 15:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3577875</link>
    </item>
    <item>
      <title>Catch Up on Tribune Watchdog Reporting: 10 Reports That Got Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3574470</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Oct. 23--On Wednesday, the Tribune featured reports updating two of its major watchdog projects this year -- &quot;Clout Goes to College,&quot; which exposed the University of Illinois admissions scandal, and &quot;Compromised Care,&quot; which reported that elderly and disabled nursing home residents were allegedly assaulted, raped and even killed by mentally ill criminals also living in the facilities. &lt;/li&gt;&lt;li&gt;Crestwood's tainted water &lt;/li&gt;&lt;li&gt;What we found: Crestwood's secret use of a polluted well for more than two decades remained secret until April, when the Tribune reported that residents in the southwest suburb unknowingly had been drinking tainted water.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3574470>[More...]</a>]]></description>
      <pubDate>Fri, 23 Oct 2009 09:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WFMI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3574470</link>
    </item>
    <item>
      <title>MandT Reports 41% Increase in Profits for Third Quarter</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3568337</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Oct. 21--M&amp;T Bank Corp. said Tuesday that third-quarter profits rose by 41 percent, fueled by a pair of acquisitions in Maryland, below-average loan losses, a higher profit margin and more fees. &lt;/li&gt;&lt;li&gt;The Buffalo-based bank reported net income of $127.7 million, or 97 cents per share, up from $91.2 million, or 82 cents per share, in the same three-month period a year ago. &lt;/li&gt;&lt;li&gt;That included an after-tax gain of $18 million, or 15 cents per share, from its government-assisted takeover of failed Bradford Bank in the Baltimore area, a transaction through which the Federal Deposit Insurance Corp. will reimburse M&amp;T for most loan losses.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3568337>[More...]</a>]]></description>
      <pubDate>Wed, 21 Oct 2009 15:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MTB</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PBKS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3568337</link>
    </item>
    <item>
      <title>MandTreports 41% Increase in Profits for Third Quarter</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3568023</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Oct. 21--M&amp;T Bank Corp. said Tuesday that third-quarter profits rose by 41 percent, fueled by a pair of acquisitions in Maryland, below-average loan losses, a higher profit margin and more fees. &lt;/li&gt;&lt;li&gt;The Buffalo-based bank reported net income of $127.7 million, or 97 cents per share, up from $91.2 million, or 82 cents per share, in the same three-month period a year ago. &lt;/li&gt;&lt;li&gt;That included an after-tax gain of $18 million, or 15 cents per share, from its government-assisted takeover of failed Bradford Bank in the Baltimore area, a transaction through which the Federal Deposit Insurance Corp. will reimburse M&amp;T for most loan losses.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3568023>[More...]</a>]]></description>
      <pubDate>Wed, 21 Oct 2009 11:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MTB</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PBKS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3568023</link>
    </item>
    <item>
      <title>Clinical Data, Inc. Reports Second Quarter Fiscal 2010 Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3618097</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Completed a public offering which generated approximately $47.4   million in gross proceeds&lt;/li&gt;&lt;li&gt;&quot;The majority of our resources remain focused on driving our late-stage   products toward key development milestones, several of which we   anticipate over the next few quarters,&quot; said Drew Fromkin, Clinical   Data's President and Chief Executive Officer. &lt;/li&gt;&lt;li&gt;Financial Results for the Three Months   Ended September 30, 2009&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3618097>[More...]</a>]]></description>
      <pubDate>Mon, 09 Nov 2009 11:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLDA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3618097</link>
    </item>
    <item>
      <title>Synta Pharmaceuticals Reports Third Quarter 2009 Financial Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3605706</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company   focused on discovering, developing, and commercializing small molecule   drugs to treat severe medical conditions, today reported financial   results for the quarter ended September 30, 2009.&lt;/li&gt;&lt;li&gt;In the third quarter, Synta recognized total revenue of $130.4 million,   of which $114.6 million was related to the acceleration of unrecognized   deferred license and milestone revenue in connection with the   termination of the agreement with GlaxoSmithKline for the development of   elesclomol. &lt;/li&gt;&lt;li&gt;General and administrative expenses were $3.1 million for the   third quarter in 2009 compared to $3.7 million for the same period in   2008.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3605706>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 11:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CTHP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SNTA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3605706</link>
    </item>
    <item>
      <title>Celldex Therapeutics Announces Completed Acquisition of CuraGen Corporation</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3520640</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced today the successful   completion of its acquisition of CuraGen Corporation (Nasdaq: CRGN)   pursuant to the previously disclosed Agreement and Plan of Merger, dated   as of May 28, 2009, by and among CuraGen, Celldex and Celldex's merger   subsidiary, Cottrell Merger Sub, Inc. The Agreement and Plan of Merger   was approved by CuraGen's stockholders and the issuance of shares of   Celldex common stock was approved by Celldex's stockholders at special   stockholder meetings held on September 30, 2009. &lt;/li&gt;&lt;li&gt;Concurrent with the   closing of the merger, Celldex added one position to its Board of   Directors and Dr. Timothy Shannon, President and Chief Executive Officer   of CuraGen, joined the Celldex Board of Directors.&lt;/li&gt;&lt;li&gt;&quot;Celldex is focused on advancing our pipeline of targeted   immunotherapeutics and we look forward to integrating CuraGen's assets   to augment our Precision Targeted Immunotherapy Platform,&quot; stated   Anthony Marucci, President and Chief Executive Officer of Celldex.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3520640>[More...]</a>]]></description>
      <pubDate>Thu, 01 Oct 2009 18:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLDX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRGN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3520640</link>
    </item>
    <item>
      <title>Celldex and CuraGen Stockholders Approve Acquisition of CuraGen Corporation</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3517478</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Celldex Therapeutics, Inc. (Nasdaq: CLDX) and CuraGen Corporation   (Nasdaq: CRGN) announced that, at special meetings held earlier today,   Celldex's stockholders approved the issuance of shares of Celldex common   stock pursuant to the previously disclosed Agreement and Plan of Merger,   dated as of May 28, 2009, by and among Celldex, Cottrell Merger Sub,   Inc. and CuraGen, and that CuraGen's stockholders approved the Agreement   and Plan of Merger.&lt;/li&gt;&lt;li&gt;Celldex   will issue approximately 16,629,981 shares of its common stock in   exchange for all outstanding shares of CuraGen common stock in   connection with the merger.&lt;/li&gt;&lt;li&gt;About Celldex Therapeutics, Inc.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3517478>[More...]</a>]]></description>
      <pubDate>Wed, 30 Sep 2009 22:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLDX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRGN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3517478</link>
    </item>
    <item>
      <title>Celldex Therapeutics Announces Appointment of Larry Ellberger As Chairman of the Board</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3459935</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that Larry   Ellberger has been appointed Chairman of the Board of Directors,   effective September 3, 2009. &lt;/li&gt;&lt;li&gt;Mr. Ellberger has been an independent   member of the Celldex Board of Directors since the merger in March 2008   between Celldex and AVANT Immunotherapeutics, Inc., and was a member of   the AVANT Board since 2003. &lt;/li&gt;&lt;li&gt;During his 30 years in the pharmaceutical   and biotechnology industries, Mr. Ellberger had served as Board member   and Chief Executive Officer of PDI, Inc., Chairman of the Board of Omrix   Biopharmaceuticals, Inc. (which was purchased by Johnson &amp; Johnson in   2008), as well as held senior executive positions at W.R. Grace &amp; Co.,   American Cyanamid Company and Powderject Ltd. In addition to his current   position as Founding Partner of HVA, a healthcare transaction advisory   firm, Mr. Ellberger is a Director of TransPharma Medical Ltd. and the   Jewish Children's Museum.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3459935>[More...]</a>]]></description>
      <pubDate>Fri, 04 Sep 2009 20:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLDX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRGN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GRA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PDII</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3459935</link>
    </item>
    <item>
      <title>Seattle Genetics Announces Exercise of Over-Allotment Option</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3412935</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that the   underwriters of its previously announced public offering of common stock   have exercised in full their option to purchase an additional 1,650,000   shares of common stock. &lt;/li&gt;&lt;li&gt;Seattle Genetics anticipates using the proceeds from this offering to   fund research and development efforts, including manufacturing   activities and clinical trials for its proprietary product candidates,   build-out of a commercial infrastructure and for general corporate   purposes, including working capital.&lt;/li&gt;&lt;li&gt;J.P. Morgan Securities Inc. and Goldman, Sachs &amp; Co. are acting as joint   book-running managers of the offering.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3412935>[More...]</a>]]></description>
      <pubDate>Thu, 13 Aug 2009 14:00:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3412935</link>
    </item>
    <item>
      <title>Seattle Genetics Announces Pricing of Public Offering of Common Stock</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3409628</guid>
      <description><![CDATA[Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $10.75 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $118.2 million. The offering is expected to close on or about August 17, 2009, subject to customary closing conditions. The company has also granted the underwriters a 30-day option to purchase up to an aggregate of 1,650,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are being sold by Seattle Genetics.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3409628>[More...]</a>]]></description>
      <pubDate>Tue, 11 Aug 2009 21:44:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3409628</link>
    </item>
    <item>
      <title>Seattle Genetics Announces Proposed Public Offering of Common Stock</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3405247</guid>
      <description><![CDATA[Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it is offering to sell, subject to market and other conditions, 9,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Seattle Genetics also intends to grant the underwriters a 30-day option to purchase up to an aggregate of 1,350,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by Seattle Genetics. J.P. Morgan Securities Inc. and Goldman, Sachs &amp; Co. are acting as joint book-running managers of the proposed offering.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3405247>[More...]</a>]]></description>
      <pubDate>Mon, 10 Aug 2009 20:03:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3405247</link>
    </item>
    <item>
      <title>Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with MedImmune</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3405683</guid>
      <description><![CDATA[Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with MedImmune, LLC, a wholly owned subsidiary of AstraZeneca. The milestone was triggered by MedImmune’s initiation of a phase I clinical trial of MEDI-547, its anti-EphA2 ADC for solid tumors.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3405683>[More...]</a>]]></description>
      <pubDate>Mon, 10 Aug 2009 13:11:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3405683</link>
    </item>
    <item>
      <title>Clinical Data, Inc. Reports First Quarter Fiscal 2009 Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3403915</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Clinical Data, Inc. (NASDAQ: CLDA) today announced operational and   financial results for the first fiscal quarter ended June 30, 2009.   &lt;/li&gt;&lt;li&gt;The positive results from the second Phase   III trial of vilazodone will contribute to a comprehensive new drug   application (NDA) anticipated to be submitted to the U.S. Food and Drug   Administration (FDA) by year end. &lt;/li&gt;&lt;li&gt;The Company also reported that gross   revenue for Clinical Data's PGxHealth FAMILION&amp;#174;   genetic testing business grew $1.7 million or 81% to $3.7 million   compared to the same period a year ago.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3403915>[More...]</a>]]></description>
      <pubDate>Mon, 10 Aug 2009 11:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CLDA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3403915</link>
    </item>
    <item>
      <title>Form  4          SEATTLE GENETICS INC      For: Dec 02  Filed by: Hoth Daniel Floyd JR (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3689525</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3689525>[More...]</a>]]></description>
      <pubDate>Fri, 04 Dec 2009 22:24:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">SGEN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3689525</link>
    </item>
    <item>
      <title>Form  4          MICROMET, INC.            For: Dec 01  Filed by: Fagerberg Jan (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3685715</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3685715>[More...]</a>]]></description>
      <pubDate>Thu, 03 Dec 2009 20:40:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">MITI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3685715</link>
    </item>
    <item>
      <title>Form  4          IMMUNOGEN INC             For: Nov 24  Filed by: LAMBERT JOHN (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3665037</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3665037>[More...]</a>]]></description>
      <pubDate>Wed, 25 Nov 2009 13:55:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">IMGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3665037</link>
    </item>
    <item>
      <title>Form  4          IMMUNOGEN INC             For: Nov 19  Filed by: SAYARE MITCHEL (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3658183</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3658183>[More...]</a>]]></description>
      <pubDate>Mon, 23 Nov 2009 17:51:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">IMGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3658183</link>
    </item>
    <item>
      <title>Form  4          IMMUNOGEN INC             For: Nov 18  Filed by: LAMBERT JOHN (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3655332</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3655332>[More...]</a>]]></description>
      <pubDate>Fri, 20 Nov 2009 21:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">IMGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3655332</link>
    </item>
    <item>
      <title>Form  4          IMMUNOGEN INC             For: Nov 11  Filed by: PIEN HOWARD H (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3633642</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3633642>[More...]</a>]]></description>
      <pubDate>Fri, 13 Nov 2009 16:05:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">IMGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3633642</link>
    </item>
    <item>
      <title>Form  3          IMMUNOGEN INC             For: Nov 11  Filed by: PIEN HOWARD H (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3633635</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3633635>[More...]</a>]]></description>
      <pubDate>Fri, 13 Nov 2009 16:03:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">IMGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3633635</link>
    </item>
    <item>
      <title>Form  4          IMMUNOGEN INC             For: Nov 11  Filed by: MCCLUSKI STEPHEN C (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3633630</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3633630>[More...]</a>]]></description>
      <pubDate>Fri, 13 Nov 2009 15:59:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">IMGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3633630</link>
    </item>
    <item>
      <title>Form  4          MICROMET, INC.            For: Aug 29  Filed by: PHILLIPS BARCLAY A (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3631253</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3631253>[More...]</a>]]></description>
      <pubDate>Thu, 12 Nov 2009 20:38:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">MITI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3631253</link>
    </item>
    <item>
      <title>Form  4          IMMUNOGEN INC             For: Nov 11  Filed by: SAYARE MITCHEL (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3631167</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3631167>[More...]</a>]]></description>
      <pubDate>Thu, 12 Nov 2009 19:57:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">IMGN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3631167</link>
    </item>
    <atom:link href="http://www.istockanalyst.com/widget/customsymbolfeed.aspx?symbols=ADC,ASCO,CLDA,CRGN,DNA,IMGN,MITI,SGEN,SGN,SNTA," rel="self" type="application/rss+xml" />
  </channel>
</rss>